<DOC>
	<DOCNO>NCT02576275</DOCNO>
	<brief_summary>This study evaluate efficacy safety duvelisib combination bendamustine rituximab ( DBR ) v placebo combination bendamustine rituximab ( PBR ) subject previously-treated indolent non-Hodgkin lymphoma ( iNHL ) .</brief_summary>
	<brief_title>A Study Duvelisib Combination With Rituximab Bendamustine v Placebo Combination With Rituximab Bendamustine Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma ( BRAVURA )</brief_title>
	<detailed_description>Study IPI-145-22 international , multicenter , randomize , double-blind , placebo-controlled , two-arm Phase 3 study design evaluate efficacy safety DBR v PBR subject previously-treated iNHL ( include follicular lymphoma [ FL ] , small lymphocytic lymphoma [ SLL ] marginal zone lymphoma [ MZL ] ) . Approximately 600 subject receive 25 mg duvelisib placebo , orally BID 28 day continuous cycle , combination 375 mg/m2 rituximab give Day 1 Cycles 1-6 90 mg/m2 bendamustine give Day 1 Day 2 Cycles 1-6 . Subjects receive duvelisib disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Diagnosis iNHL one follow histologic subtypes grade : Follicular lymphoma ( FL ) Grade 1 , 2 , 3a Small lymphocytic lymphoma ( SLL ) Marginal zone lymphoma ( MZL ) ( splenic , nodal , extranodal ) Have receive following systemic treatment iNHL : antiCD20 antibody ; chemotherapy At least 1 measurable disease lesion &gt; 1.5 cm least one dimension compute tomography ( CT ) /CTPET magnetic resonance imaging ( MRI ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 ( corresponds Karnofsky Performance Status [ ( KPS ) ≥60 % ] ) Clinical evidence transformation aggressive subtype lymphoma grade 3B FL Refractory bendamustine + rituximab therapy singleagent bendamustine 120 mg/m2 , refractory define : − Progression disease receive within 6 month complete treatment Severe allergic anaphylactic reaction monoclonal antibody therapy , murine protein , know hypersensitivity study drug Received prior allogeneic transplant Received prior treatment phosphoinositide3kinase ( PI3K ) inhibitor Infection hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) . History tuberculosis treatment within two year prior randomization History chronic liver disease , venoocclusive disease , alcohol abuse Ongoing treatment chronic immunosuppressant ( e.g. , cyclosporine ) systemic steroid &gt; 20 mg prednisone ( equivalent ) daily ( QD ) Ongoing treatment systemic bacterial , fungal , viral infection screen Unable receive prophylactic treatment pneumocystis , herpes simplex virus ( HSV ) , herpes zoster ( VZV ) screen Concurrent active malignancy adequately treat nonmelanoma skin cancer lentigo maligna without evidence invasive disease adequately treat cervical carcinoma situ without evidence disease History stroke , unstable angina , myocardial infarction , ventricular arrhythmia require medication pacemaker within last 6 month prior screen History progressive multifocal leukoencephalopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Phase 3</keyword>
	<keyword>iNHL</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>FL</keyword>
	<keyword>PI3K</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>SLL</keyword>
	<keyword>Marginal Zone Lymphoma</keyword>
	<keyword>MZL</keyword>
</DOC>